Related references
Note: Only part of the references are listed.Galectin-3 regulates apoptosis and doxorubicin chemoresistance in papillary thyroid cancer cells
Chi-Iou Lin et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2009)
Galectin-3 in urine of cancer patients: stage and tissue specificity
Kiruthika Balasubramanian et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2009)
Prognostic factors of secondary cytoreductive surgery for patients with recurrent epithelial ovarian cancer
Kidong Kim et al.
Journal of Gynecologic Oncology (2009)
The Future of Targeted Therapies in Ovarian Cancer
Susana Banerjee et al.
ONCOLOGIST (2009)
Synthetic Galectin-3 Inhibitor Increases Metastatic Cancer Cell Sensitivity to Taxol-Induced Apoptosis In Vitro and In Vivo
Vladislav V. Glinsky et al.
NEOPLASIA (2009)
Biological Modulation by Lectins and Their Ligands in Tumor Progression and Metastasis
Avraham Raz et al.
Anti-Cancer Agents in Medicinal Chemistry (2008)
Galectins: structure, function and therapeutic potential
Ri-Yao Yang et al.
EXPERT REVIEWS IN MOLECULAR MEDICINE (2008)
Epidermal growth factor receptor expression in serous ovarian carcinoma: An immunohistochemical study with galectin-3 and cyclin D1 and outcome
Hermann Brustmann
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2008)
Galectin-3 Upregulation During Tumor Progression in Head and Neck Cancer
Sven Saussez et al.
LARYNGOSCOPE (2008)
Galectin-3 may contribute to Cisplatin resistance in clear cell carcinoma of the ovary
T. Oishi et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2007)
Galectins: matricellular glycan-binding proteins linking cell adhesion, migration, and survival
M. T. Elola et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2007)
Transport of galectin-3 between the nucleus and cytoplasm. I. Conditions and signals for nuclear import
Peter J. Davidson et al.
GLYCOBIOLOGY (2006)
Increased expressions of claudin-1 and claudin-7 during the progression of cervical neoplasia
JW Lee et al.
GYNECOLOGIC ONCOLOGY (2005)
A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics
Y Takei et al.
CANCER RESEARCH (2004)
Modified citrus pectin (MCP) increases the prostate-specific antigen doubling time in men with prostate cancer: a phase II pilot study
BW Guess et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2003)
Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin
P Nangia-Makker et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2002)
Stable suppression of tumorigenicity by virus-mediated RNA interference
TR Brummelkamp et al.
CANCER CELL (2002)
Shuttling of galectin-3 between the nucleus and cytoplasm
PJ Davidson et al.
GLYCOBIOLOGY (2002)
Expression of galectins in cancer: A critical review
F van den Brule et al.
GLYCOCONJUGATE JOURNAL (2002)
Galectin-3 and metastasis
Y Takenaka et al.
GLYCOCONJUGATE JOURNAL (2002)
Extracellular functions of galectin-3
J Ochieng et al.
GLYCOCONJUGATE JOURNAL (2002)
Expression of endogenous Galectin-1 and Galectin-3 in intrahepatic cholangiocarcinoma
T Shimonishi et al.
HUMAN PATHOLOGY (2001)